• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022

    12/27/22 10:00:53 AM ET
    $AMTI
    $GIAC
    $IPSC
    $LEV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Business Services
    Finance
    Get the next $AMTI alert in real time by email

    Upgrades

    See all analyst ratings upgrades.

    Downgrades

    For Applied Molecular Transport Inc (NASDAQ:AMTI), SVB Leerink downgraded the previous rating of Outperform to Market Perform. In the third quarter, Applied Molecular showed an EPS of $0.65, compared to $0.68 from the year-ago quarter. The stock has a 52-week-high of $14.94 and a 52-week-low of $0.39. At the end of the last trading period, Applied Molecular closed at $0.43.

    See all analyst ratings downgrades.

    Initiations

    Northland Capital Markets initiated coverage on The Lion Electric Co (NYSE:LEV) with an Outperform rating. The price target for Lion Electric is set to $5.00. Lion Electric earned $0.09 in the third quarter, compared to $0.60 in the year-ago quarter. At the moment, the stock has a 52-week-high of $10.18 and a 52-week-low of $1.83. Lion Electric closed at $2.00 at the end of the last trading period.

    With a Buy rating, Chardan Capital initiated coverage on Gesher I Acquisition Corp (NASDAQ:GIAC). The price target seems to have been set at $13.00 for Gesher I Acquisition.

    Chardan Capital initiated coverage on Century Therapeutics Inc (NASDAQ:IPSC) with a Buy rating. The price target for Century Therapeutics is set to $19.00. Century Therapeutics earned $0.53 in the third quarter, compared to $0.48 in the year-ago quarter. The stock has a 52-week-high of $19.39 and a 52-week-low of $5.48. At the end of the last trading period, Century Therapeutics closed at $5.67.

    See all analyst ratings initiations.

    Get the next $AMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTI
    $GIAC
    $IPSC
    $LEV

    CompanyDatePrice TargetRatingAnalyst
    Century Therapeutics Inc.
    $IPSC
    2/25/2026Buy
    TD Cowen
    The Lion Electric Company
    $LEV
    8/12/2024$1.50 → $1.00Buy → Neutral
    DA Davidson
    Century Therapeutics Inc.
    $IPSC
    8/8/2024$6.00Buy
    Rodman & Renshaw
    Century Therapeutics Inc.
    $IPSC
    8/28/2023$28.00 → $5.00Overweight → Neutral
    JP Morgan
    The Lion Electric Company
    $LEV
    8/4/2023$2.75Outperform → Sector Perform
    National Bank Financial
    The Lion Electric Company
    $LEV
    3/27/2023$7.00Buy
    R. F. Lafferty
    The Lion Electric Company
    $LEV
    3/20/2023$2.00Market Perform
    BMO Capital Markets
    The Lion Electric Company
    $LEV
    2/15/2023$3.00Equal Weight
    Barclays
    More analyst ratings

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates

    CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H 2027CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion™ 5.0, on track to enter the clinic in 2026Strengthened balance sheet and cash runway extended into 1Q 2029 from oversubscribed $135 million private placement in January 2026 PHILADELPHIA, March 12, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoi

    3/12/26 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics to Participate in Upcoming Investor Conferences in March

    PHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today announced that the company will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat at 9:50 a.m. ET on Wednesday, March 4, 2026, in Boston, MA. Leerink Partners Global Healthcare Conference: Fireside chat at 4:20 p.m. ET on Tuesday, March 10, 2026, in Miami, FL. A live webcast of the presentations will be available on the Investors page of Century's

    2/25/26 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

    New York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells clinical trial analysis report delivers important insights into ongoing research of 15+ pipeline iPSC-derived NK cells drugs, clinical strategies, upcoming therapeutics, and commercial analysis. DelveInsight's 'IPSC-derived NK Cells Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for IPSC-derived NK cells across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitiv

    2/16/26 1:00:00 PM ET
    $FATE
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $GIAC
    $IPSC
    $LEV
    SEC Filings

    View All

    SEC Form PRE 14A filed by Century Therapeutics Inc.

    PRE 14A - Century Therapeutics, Inc. (0001850119) (Filer)

    4/16/26 4:07:35 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Century Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Century Therapeutics, Inc. (0001850119) (Filer)

    3/26/26 4:42:19 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Century Therapeutics Inc.

    424B5 - Century Therapeutics, Inc. (0001850119) (Filer)

    3/26/26 4:40:45 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Century Therapeutics

    TD Cowen initiated coverage of Century Therapeutics with a rating of Buy

    2/25/26 7:49:49 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lion Electric downgraded by DA Davidson with a new price target

    DA Davidson downgraded Lion Electric from Buy to Neutral and set a new price target of $1.00 from $1.50 previously

    8/12/24 7:56:29 AM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    Rodman & Renshaw initiated coverage on Century Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00

    8/8/24 10:22:51 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Cowan Chad bought $49,252 worth of shares (58,060 units at $0.85), increasing direct ownership by 6% to 1,045,087 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/29/25 4:52:27 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $30,352 worth of shares (52,000 units at $0.58), increasing direct ownership by 2% to 3,322,990 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    12/16/25 6:38:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Pfeiffenberger Brent bought $17,328 worth of shares (35,000 units at $0.50), increasing direct ownership by 1% to 3,271,453 units (SEC Form 4)

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    11/20/25 6:02:42 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Murphy Martin Patrick

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    4/10/26 5:07:53 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Murphy Martin Patrick

    3 - Century Therapeutics, Inc. (0001850119) (Issuer)

    4/10/26 5:02:04 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Cowan Chad

    4 - Century Therapeutics, Inc. (0001850119) (Issuer)

    4/3/26 7:18:34 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Leadership Updates

    Live Leadership Updates

    View All

    Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

    PHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the appointments of Han Lee, Ph.D., M.B.A., and Martin Murphy, Ph.D., to its Board of Directors. As part of their appointments, Dr. Lee will serve as a member of the Audit and the Compensation Committees and Dr. Murphy will serve as a member of the Compensation and the Nominating and Corporate Governance Committees. "We are pleased to welcome Dr. Lee and Dr. Murphy to our Board at an important time for Century as we execute with discipline and

    12/9/25 8:00:00 AM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LION ELECTRIC FILES APPLICATION FOR CREDITOR PROTECTION UNDER THE CCAA

    MONTREAL, Dec. 18, 2024 /PRNewswire/ - The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, announced today that the Company and its subsidiaries have applied to the Superior Court of Quebec (Commercial Division) (the "Court") for an initial order to seek protection from their creditors under the Companies' Creditors Arrangement Act ("CCAA"). The Company and its subsidiaries also intend to seek recognition of the CCAA proceedings in the United States under Chapter 15 of the Bankruptcy Code. In its application for an initial order, the Company seeks the approval of a formal sale and investment s

    12/18/24 7:30:00 AM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    LION ELECTRIC ANNOUNCES RESULTS OF ANNUAL SHAREHOLDERS MEETING

    MONTREAL, May 15, 2024 /PRNewswire/ - The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today held its annual meeting of shareholders (the "Meeting") as a virtual meeting. A total of 124,783,928 common shares (representing approximately 55.16% of all issued and outstanding common shares of the Company) were represented online or by proxy at the Meeting. Lion hereby announces that shareholders of the Company (the "Shareholders") voted in favour of all items of business put forth at the Meeting by the Company. The complete voting results for each item of business at the Meeting are presented be

    5/15/24 6:21:00 PM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Financials

    Live finance-specific insights

    View All

    LION ELECTRIC ANNOUNCES THIRD QUARTER 2024 RESULTS

    MONTREAL, Nov. 6, 2024 /PRNewswire/ - The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced its financial and operating results for the third quarter of fiscal year 2024, which ended on September 30, 2024. Lion reports its results in US dollars and in accordance with International Financial Reporting Standards ("IFRS"). Q3 2024 FINANCIAL HIGHLIGHTS Revenue of $30.6 million, down $49.7 million, as compared to $80.3 million in Q3 2023.Delivery of 89 vehicles, a decrease of 156 vehicles, as compared to the 245 delivered in Q3 2023.Gross loss of $16.0 million, as compared to gross p

    11/6/24 5:05:00 PM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    LION ELECTRIC ANNOUNCES THIRD QUARTER 2024 RESULTS RELEASE DATE

    MONTREAL, Nov. 1, 2024 /PRNewswire/ - The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced that it will release its third quarter 2024 results on November 6, 2024, after markets close. A conference call and webcast will be held on the same day, at 5:30 p.m. (Eastern Time) to discuss the results. To participate in the conference call, please dial (404) 975-4839 or (833) 470-1428 (toll free) using the Access Code 946933. A live webcast of the conference call will also be available at www.thelionelectric.com under the "Events and Presentation" page of the "Investors" section. An ar

    11/1/24 5:15:00 PM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    LION ELECTRIC ANNOUNCES SECOND QUARTER 2024 RESULTS

    MONTREAL, July 31, 2024 /PRNewswire/ - The Lion Electric Company (NYSE:LEV) (TSX:LEV) ("Lion" or the "Company"), a leading manufacturer of all-electric medium and heavy-duty urban vehicles, today announced its financial and operating results for the second quarter of fiscal year 2024, which ended on June 30, 2024. Lion reports its results in US dollars and in accordance with International Financial Reporting Standards ("IFRS"). Q2 2024 FINANCIAL HIGHLIGHTS Revenue of $30.3 million, down $27.7 million, as compared to $58.0 million in Q2 2023.Delivery of 101 vehicles, a decrease of 98 vehicles, as compared to the 199 delivered in Q2 2023. Less vehicles were delivered due to the impact of the

    7/31/24 6:30:00 AM ET
    $LEV
    Auto Manufacturing
    Consumer Discretionary

    $AMTI
    $GIAC
    $IPSC
    $LEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Century Therapeutics Inc.

    SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)

    11/27/24 6:51:58 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 5:46:35 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Century Therapeutics Inc.

    SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)

    11/14/24 4:08:17 PM ET
    $IPSC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care